Condition

Cervical Cancer

ClinicalTrials.gov condition label

Clinical trials268

Recruiting65

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Guaraná Supplementation for Cancer-Related FatigueNCT07816263 · 2026-06-20

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsNCT07623369 · 2026-06-11

Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line ImmunotherapyNCT07676461 · 2026-06-11

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsNCT07524322 · 2026-06-01

18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsNCT07557225 · 2026-04-27

Navigation Intervention for Adolescent and Young Adult Cancer SurvivorsNCT07406087 · 2026-03-15

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)NCT07225530 · 2026-02-23

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 · 2026-02-23

Distance-Based Exercise to Preserve Function and Prevent DisabilityNCT07059884 · 2026-02-11

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialNCT07227077 · 2026-02-07

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in IndiaNCT07209917 · 2026-02-01

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsNCT07586826 · 2025-12-22

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168 · 2025-11-07

Patient Preference for Subcutaneous vs. Intravenous Immune TherapyNCT07223424 · 2025-11-04

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNCT07182149 · 2025-10-30

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsNCT07109726 · 2025-09-23

Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-careNCT06850402 · 2025-09-22

DESTINY-PANTUMOUR04NCT07124000 · 2025-09-18

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsNCT06814496 · 2025-09-08

A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)NCT06232083 · 2025-09-01

A Study of YL202 in Patients With Advanced Solid TumorsNCT07202364 · 2025-08-04

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasNCT06999187 · 2025-06-03

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced MalignanciesNCT07064018 · 2025-04-30

Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)NCT07782164 · 2025-04-18

A Study of MT-4561 in Patients With Various Advanced Solid TumorsNCT06943521 · 2025-04-18

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)NCT06630611 · 2025-01-15

Trop2-targeted immunoPET Imaging of Solid TumorsNCT06851663 · 2024-12-23

Community, Home-based Education, Screening Services Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in NigeriaNCT06751030 · 2024-12-03

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid TumorNCT07433283 · 2024-11-12

A Study of VET3-TGI in Patients With Solid TumorsNCT06444815 · 2024-09-16

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069 · 2024-07-01

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsNCT06239194 · 2024-06-12

AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)NCT06004011 · 2024-05-01

A Study of MGC026 in Participants With Advanced Solid TumorsNCT06242470 · 2024-03-06

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsNCT06172478 · 2024-02-26

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsNCT06265025 · 2024-02-20

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsNCT06293898 · 2024-02-09

ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat ServicesNCT06128304 · 2023-11-13

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01

Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)NCT06691776 · 2023-08-29

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsNCT05983432 · 2023-08-08

a Single-arm, Single-center, Open Clinical StudyNCT06431100 · 2023-07-19

A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)NCT06028724 · 2023-05-26

Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South AfricaNCT05413798 · 2023-05-11

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid TumorsNCT06508307 · 2023-04-26

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsNCT05283330 · 2022-12-22

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)NCT05579366 · 2022-12-07

NYSCF Scientific Discovery BiobankNCT06203106 · 2022-11-10

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerNCT05483491 · 2022-09-26

Improving Care for Rural Patients With Solid TumorsNCT04916990 · 2022-09-01

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseNCT05366881 · 2022-05-03

Early Ageing During Therapy in AYA Cancer PatientsNCT05062707 · 2022-02-10

Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsNCT05187338 · 2021-11-01

A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674 · 2021-09-29

A Beta-only IL-2 ImmunoTherapY StudyNCT05086692 · 2021-08-27

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsNCT04977453 · 2021-08-02

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709 · 2021-05-27

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsNCT04038619 · 2021-02-01

A Multicenter Cancer Biospecimen Collection StudyNCT04510129 · 2020-02-05

Common interventions

Leading sponsors

National Cancer Institute (NCI)9 AstraZeneca5 Duke University5 Johns Hopkins University5 M.D. Anderson Cancer Center5 The University of Texas Health Science Center, Houston5 UNC Lineberger Comprehensive Cancer Center5 Incyte Corporation3 Merck Sharp & Dohme LLC3 NGM Biopharmaceuticals, Inc3 Roswell Park Cancer Institute3 University of California, San Diego3 University of Washington3 AIDS Malignancy Consortium2 Albert Einstein College of Medicine2

Trial status mix

COMPLETED118

RECRUITING65

ACTIVE_NOT_RECRUITING22

TERMINATED22

UNKNOWN17

NOT_YET_RECRUITING15

WITHDRAWN5

ENROLLING_BY_INVITATION2

SUSPENDED2

Phase mix

PHASE199

NA79

PHASE266

PHASE39

PHASE45

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.